OliLux Biosciences was founded by Mireille Kamariza and Carolyn Bertozzi at Stanford University with a core mission to innovate tuberculosis (TB) detection and treatment management. The company’s primary product is DMN-Tre, a novel small molecule designed to provide rapid and low-cost TB detection alternatives. OliLux focuses on addressing the global health challenge of TB by offering efficient diagnostic solutions that can be deployed in resource-limited settings.
Notable affiliated individuals include Mireille Kamariza, the Founder and CEO, and Carolyn Bertozzi, a Founder and Scientific Advisor. OliLux has garnered attention for its groundbreaking work in TB diagnostics, leveraging advanced scientific research to create impactful healthcare solutions. The company’s achievements in developing DMN-Tre highlight its potential to significantly improve TB detection rates and treatment outcomes, contributing to global health advancements.
